Total Payments
$96,762
2024 Payments
$25,242
Companies
31
Transactions
286
Medicare Patients
6,041
Medicare Billing
$3.9M
Payment Breakdown by Category
Other$67,695 (70.0%)
Food & Beverage$14,881 (15.4%)
Consulting$10,825 (11.2%)
Travel$3,346 (3.5%)
Education$14.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,831 | 19 | 66.0% |
| Food and Beverage | $14,881 | 231 | 15.4% |
| Consulting Fee | $10,825 | 5 | 11.2% |
| Travel and Lodging | $3,346 | 16 | 3.5% |
| Current or prospective ownership or investment interest | $2,352 | 5 | 2.4% |
| Honoraria | $1,512 | 1 | 1.6% |
| Education | $14.13 | 1 | 0.0% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$96,762
278 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $70,127 | 97 | $0 (2024) |
| Alimera Sciences, Inc. | $7,168 | 26 | $0 (2024) |
| Genentech USA, Inc. | $5,863 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,396 | 14 | $0 (2020) |
| Apellis Pharmaceuticals, Inc. | $3,948 | 17 | $0 (2024) |
| US Retina LLC | $2,352 | 13 | $0 (2024) |
| ABBVIE INC. | $495.66 | 21 | $0 (2024) |
| Coherus Biosciences Inc. | $375.00 | 7 | $0 (2023) |
| Astellas Pharma US Inc | $264.00 | 5 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $236.84 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,242 | 63 | Regeneron Healthcare Solutions, Inc. ($15,249) |
| 2023 | $51,293 | 81 | Regeneron Healthcare Solutions, Inc. ($44,945) |
| 2022 | $11,665 | 40 | Regeneron Healthcare Solutions, Inc. ($9,409) |
| 2021 | $1,545 | 15 | Alimera Sciences, Inc. ($697.00) |
| 2020 | $4,718 | 18 | Novartis Pharmaceuticals Corporation ($4,039) |
| 2019 | $1,281 | 30 | US Retina LLC ($473.75) |
| 2018 | $476.85 | 20 | Regeneron Healthcare Solutions, Inc. ($98.28) |
| 2017 | $540.84 | 19 | Regeneron Healthcare Solutions, Inc. ($183.25) |
All Payment Transactions
286 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Ophthalmology | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/25/2024 | Apellis Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $1,512.00 | General |
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $36.88 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: EYE CARE | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: Ophthalmology | ||||||
| 10/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: EYE CARE | ||||||
| 10/18/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $151.92 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: Ophthalmology | ||||||
| 10/17/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $179.43 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $100.81 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,434.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/14/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $56.96 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/10/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $30.35 | General |
| Category: Ophthalmology | ||||||
| 09/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $972.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $81.74 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/27/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/26/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $876.75 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/13/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: Ophthalmology | ||||||
| 08/08/2024 | Surgical Specialties Corporation (us), Inc. (dba Corza Medical) | — | Food and Beverage | In-kind items and services | $53.77 | General |
| 08/02/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $798.35 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/29/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $743.75 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,243.98 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,474 | 6,270 | $1.9M | $869,941 |
| 2022 | 13 | 1,545 | 4,620 | $2.0M | $917,114 |
| 2021 | 13 | 1,498 | 4,849 | $2.1M | $1.1M |
| 2020 | 11 | 1,524 | 5,012 | $2.0M | $1.0M |
Total Patients
6,041
Total Services
20,751
Medicare Billing
$3.9M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 108 | 926 | $1.2M | $609,142 | 52.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 209 | 810 | $333,965 | $75,340 | 22.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 11 | 2,100 | $90,900 | $60,895 | 67.0% |
| 92134 | Imaging of retina | Office | 2023 | 443 | 1,181 | $97,550 | $33,247 | 34.1% |
| J3590 | Unclassified biologics | Office | 2023 | 102 | 439 | $87,800 | $30,207 | 34.4% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 243 | 306 | $55,595 | $26,954 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 149 | $31,100 | $13,649 | 43.9% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 56 | 165 | $16,500 | $7,462 | 45.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $7,945 | $3,722 | 46.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 28 | 28 | $6,075 | $2,551 | 42.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 23 | 28 | $3,350 | $1,821 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 23 | $3,290 | $1,496 | 45.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 13 | 13 | $2,650 | $1,342 | 50.6% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 22 | 31 | $2,480 | $1,100 | 44.3% |
| 92250 | Photography of the retina | Office | 2023 | 39 | 39 | $5,250 | $1,015 | 19.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 103 | 980 | $1.2M | $695,252 | 56.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 226 | 913 | $360,620 | $83,907 | 23.3% |
| J3590 | Unclassified biologics | Office | 2022 | 120 | 575 | $115,000 | $38,045 | 33.1% |
| 92134 | Imaging of retina | Office | 2022 | 445 | 1,303 | $106,575 | $36,042 | 33.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 287 | 389 | $71,130 | $31,304 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 135 | $26,620 | $12,386 | 46.5% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 53 | 53 | $11,455 | $4,474 | 39.1% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 47 | 89 | $8,900 | $4,333 | 48.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 31 | 33 | $6,900 | $3,017 | 43.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 35 | 47 | $5,585 | $2,916 | 52.2% |
About Dr. Scott Westhouse, D.O
Dr. Scott Westhouse, D.O is a Ophthalmology healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1306016977.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Westhouse, D.O has received a total of $96,762 in payments from pharmaceutical and medical device companies, with $25,242 received in 2024. These payments were reported across 286 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($63,831).
As a Medicare-enrolled provider, Westhouse has provided services to 6,041 Medicare beneficiaries, totaling 20,751 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Grand Rapids, MI
- Active Since 03/10/2008
- Last Updated 03/27/2015
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1306016977
Products in Payments
- EYLEA HD (Biological) $43,083
- EYLEA (Biological) $27,000
- BEOVU (Drug) $4,101
- ILUVIEN (Drug) $3,695
- YUTIQ (Drug) $3,429
- Vabysmo (Drug) $3,061
- Syfovre (Drug) $2,326
- Susvimo (Drug) $2,287
- Cimerli (Biological) $427.87
- OZURDEX (Drug) $424.80
- Lucentis (Biological) $312.85
- EYLEA AFLIBERCEPT INJECTION (Biological) $281.53
- ACTHAR (Biological) $247.66
- Izervay (Drug) $234.85
- XIPERE (Drug) $144.13
- Iluvien (Drug) $128.50
- SUSVIMO (Drug) $112.03
- Humira (Biological) $103.03
- VISUDYNE (Drug) $95.11
- VABYSMO (Drug) $90.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Grand Rapids
Dr. Thomas Aaberg, Md, MD
Ophthalmology — Payments: $329,714
Ophthalmology $329,714
Dr. Edward Korot, M.d, M.D
Ophthalmology — Payments: $43,512
Ophthalmology $43,512
Roman Krivochenitser, M.d, M.D
Ophthalmology — Payments: $21,287
Ophthalmology $21,287
Dr. Joseph Boss, M.d, M.D
Ophthalmology — Payments: $21,268
Ophthalmology $21,268
Dr. Marcus Muallem, Md, MD
Ophthalmology — Payments: $14,992
Ophthalmology $14,992
Dr. Liliya Sutherland, D.o, D.O
Ophthalmology — Payments: $13,103
Ophthalmology $13,103